Dyslipidaemias in cancer patients.

Dyslipidaemia and cancer treatments both increase atherosclerotic cardiovascular disease (ASCVD) risk; yet, most risk prediction scores for ASCVD do not include important cancer factors and thus underestimate true ASCVD.

血脂异常和癌症治疗都会增加动脉粥样硬化性心血管疾病（ASCVD）的风险；然而，大多数ASCVD风险预测评分并未包括重要的癌症因素，因此低估了真正的ASCVD风险。

Some cancer therapies cause transient elevations of low-density lipoprotein cholesterol or triglycerides, or reduction in high-density lipoprotein cholesterol, occasionally to extreme levels requiring specific treatment and monitoring strategies.

一些癌症治疗会导致低密度脂蛋白胆固醇或甘油三酯的暂时性升高，或高密度脂蛋白胆固醇的降低，偶尔会达到需要特定治疗和监测策略的极端水平。

A range of lipid-lowering therapies can be used in cancer patients to manage cholesterol and triglycerides but of these, reliable data only exist for statins and ezetimibe for managing low-density lipoprotein cholesterol, and fibrates and Omega 3 fish oils for hypertriglyceridaemia.

在癌症患者中，可以使用一系列降脂疗法来管理胆固醇和甘油三酯，但在这些疗法中，只有他汀类药物和依折麦布用于管理低密度脂蛋白胆固醇，以及贝特类药物和Omega 3鱼油用于高甘油三酯血症的数据是可靠的。

There are no robust randomized controlled trials conducted in cancer patients for reduction of adverse cardiovascular events and therefore current recommendations have been extrapolated from non-cancer trials.

目前还没有在癌症患者中进行的减少不良心血管事件的强有力的随机对照试验，因此目前的建议是根据非癌症试验推断出来的。

Cancer survivors may require combination therapies; yet, trials of newer lipid-lowering therapies excluded cancer patients and hence safety and efficacy data are limited.

癌症幸存者可能需要联合治疗；然而，新型降脂疗法的试验排除了癌症患者，因此安全性和有效性数据有限。

The initiation of lipid-lowering therapy in cancer patients requires an integration of several factors, which includes a careful assessment of ASCVD risk, drug-drug interactions, side-effect profiles, and prognosis.

在癌症患者中启动降脂治疗需要综合考虑几个因素，包括仔细评估ASCVD风险、药物-药物相互作用、副作用特征和预后。

Further work is required to personalize individualized risk scores for ASCVD in cancer patients and survivors and new trials and 'real-world' or registry data would inform these existing data gaps.

需要进一步的工作来个性化癌症患者和幸存者的ASCVD个体化风险评分，并且新的试验和'真实世界'或注册数据将填补这些现有数据空白。

Beyond lipid management, the putative role of therapies such for statins as cardioprotective agent for anthracycline chemotherapy open novel avenues for further research as survival from many cancers continues to improve.

除了血脂管理，如他汀类药物作为葱环类化疗的潜在心脏保护剂的角色，随着许多癌症患者的生存率持续提高，为未来的研究开辟了新的途径。